From September 2 to 6, 2023, PUMCH made its third appearance at the China International Fair for Trade in Services (CIFTIS), showcasing the latest achievements in clinical research and translational medicine. At its own exhibition booth, it displayed multiple innovative outcomes, held two signing ceremonies for translational medicine projects, and hosted science popularization lectures by three PUMCH experts. PUMCH fully tapped into the CIFTIS platform to demonstrate, from multiple angles, the innovativeness and vitality underlying the hospital’s high-quality development over the past year.
▲The booth of PUMCH
ECMO (extracorporeal membrane oxygenation), auxiliary diagnostic equipment, surgical robots, wearable devices, and other medical research achievements drew the attention of numerous visitors. These innovative medical devices are the fruits of PUMCHers’ medical-engineering integration and translation geared towards clinical needs.
▲Vice President Yang Dungan (second from right) was being interviewed by the health-focused app of “People’s Daily”
One of the highlights of the PUMCH booth is the Huisheng-I ECMO device, which was launched in February this year. Developed in collaboration between PUMCH and China Aerospace Science and Technology Corporation, it featured China’s complete control over key technologies and core components. Its overall performance and indicators are on a par with international products of a similar category, with some indicators even outperforming them. PUMCH joined at the very beginning the joint research and development taskforce and took the lead in designing and implementing animal experiments and clinical trials. This new model breaks down barriers between professions, stresses scientific planning and coordination, and promotes collaborative innovation. That makes it an exemplary model for effectively removing the bottlenecks of high-end medical equipment in China.
Also exhibited in the PUMCH booth was China’s first knee joint surgical robot with intellectual property rights and approved for launch. PUMCH has led multiple centers nationwide in completing over 1,800 robot-assisted total knee replacement surgeries to great effects. Three products developed by the Department of Ophthalmology, PUMCH, namely a disposable anterior chamber puncture device, a magnetic particle-based chemiluminescence test kit for intraocular fluid, and a new resistance-sensing suprachoroidal injection device, are all internationally pioneering or leading products that hold potential for improving the accuracy of diagnosis and treatment of ocular fundus diseases.
▲Introduction of orthopedic robots
▲Visitors were leafing through the innovation translation manual of the Department of Ophthalmology
The PUMCH nursing team has also displayed multiple patent tranlational achievements. The intelligent pressure-based hemostasis device for arterial puncture can accurately monitor pressure and duration of application. The compression-based hemostasis device for distal radial artery puncture fills the gap in this category domestically. The “little black box” medical pressure sensor-based precise positioning and fixation device can effectively improve the accuracy of invasive pressure monitoring.
▲The nursing personnel were introducing the innovation translation achievements to visitors
On the afternoon of September 3, the Department of Radiotherapy and the Department of Neurology, PUMCH both signed cooperation agreements with their respective partner on-site, becoming one of the highlights of PUMCH during CIFTIS.
The Department of Radiotherapy, PUMCH undertook in collaboration with Our United Corporation, a medical device company in Xi’an, a key project of digital diagnostic and therapeutic equipment R&D during the 13th Five-Year Plan period, funded by the Ministry of Science and Technology of China. They successfully developed the world’s first X/γ-ray integrated radiotherapy system called TAICHI. This device combines the functions of a linear accelerator and a gamma knife, making it the only large-scale medical equipment in China that was granted the FDA Breakthrough Device Designation. The two sides will continue to deepen their cooperation. The research cooperation agreement on solutions for clinical application that they signed at CIFTIS will further advance research on and wider adoption of clinical applications.
The Department of Neurology, which has been diving deep into quantitative measurement of brain function, had more than one delightful surprise to unveil: their two products for commercialization, the ReadyGo Neurofunctional Balance Testing System and the BrainFit Digital Cognitive Function Quantitative Assessment and Training System, as well as a new agreement on translation to be signed with its partner. Professor Zhu Yicheng said: “These products are like ‘intelligent rulers’ for assessing and diagnosing neurological diseases. They can assist doctors in diagnosing, evaluating, and monitoring the treatment of patients with conditions such as stroke, Alzheimer’s disease, and Parkinson’s disease.”
▲Many visitors were intrigued by and tried the innovative products of the Department of Neurology
From September 2 to 5, three leading experts from different departments of PUMCH, namely Wang Weibin from General Surgery, Li Mengtao from Rheumatology, and Liu Zhenyu from Cardiology presented “Health Tips” from PUMCH on topics of interest to the general public, such as pancreatic cancer, rheumatoid arthritis, and hypertension.
▲Science popularization lecture by Prof. Wang Weibin
Over the past three years, PUMCH has always actively participated in CIFTIS and put on full display its outstanding achievements of “innovation-driven development”. Accumulatively, it presented dozens of commercialized independent innovations together, signed 10 agreements on-site, and 10 PUMCH experts delivered health-themed lectures. Such meaningful and diverse activities added to the substance and appeal of CIFTIS every year.
▲Vice President Yang Dungan visited the PUMCH booth
Written by Fu Tanpin and Chen Mingyan
Pictures courtesy of the CIFTIS
Edited by Xiao Xiong
Translated by Liu Haiyan
Reviewed by Wang Yao